A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
NORTHWEST BIOTHERAPEUTICS INC
NWBO
$264M
Mkt Cap
$0.17
+1.12%
NORTHWEST BIOTHERAPEUTICS INC (NWBO) has a 5-year average return on invested capital (ROIC) of -154.0%. This is below average and may indicate limited pricing power.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) has a market capitalization of $264M. It is classified as a small-cap stock.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) does not currently pay a regular dividend.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) generated $-46 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported earnings per share (EPS) of $-0.04 in its most recent fiscal year.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) has a return on equity (ROE) of 79.4%. This indicates the company generates strong returns for shareholders.
ITEM 1. BUSINESS. We are a biotechnology company focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. Our lead product candidate, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. We have completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), published the results in the JAMA Oncology peer reviewed journal, and on December 20, 2023 we submitted a Marketing Authorization Application (MAA) for commercial approval in the U.K. We plan to conduct clinical trials of DCVax-L for other solid tumor cancers in the future, when resources permit. Our second product candidate, DCVax®-Direct, is designed to treat inoperable solid tumors.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | - | - |
| Net Income | -61M | -61M | -85M | -64M | -105M | 179M |
| EPS | $-0.04 | $-0.04 | $-0.07 | $-0.06 | $-0.10 | $0.19 |
| Free Cash Flow | -46M | -46M | -58M | -54M | -53M | 38M |
| ROIC | -431.3% | -73.7% | -196.6% | -199.2% | -169.4% | -131.2% |
| Gross Margin | - | 0.0% | - | - | - | - |
| Debt/Equity | 0.00 | -1.23 | -0.86 | -0.75 | -0.33 | -0.36 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -60M | -60M | -67M | -56M | -67M | -53M |
| Operating Margin | 0.0% | 0.0% | - | - | - | - |
| ROE | 0.0% | 79.4% | 106.3% | 66.4% | 83.3% | -73.6% |
| Shares Outstanding | 1,537M | 1,537M | 1,217M | 1,073M | 1,050M | 948M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | N/A |
| R&D | 86M | 103M | 60M | 34M | 18M | 14M | 34M | 20M | 36M | 28M | 35M | 29M | 29M |
| SG&A | 17M | 18M | 11M | 12M | 23M | 16M | 54M | 33M | 33M | 30M | 33M | 33M | 33M |
| EBIT | -101M | -126M | -79M | -55M | -41M | -28M | -87M | -53M | -67M | -56M | -67M | -60M | -60M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Net Income | -136M | -115M | -86M | -74M | -54M | -21M | -530M | 179M | -105M | -64M | -85M | -61M | -61M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Non-Recurring | 0 | 53K | 0 | 0 | 3.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -179.2% | -178.4% | -118.4% | -111.8% | -168.2% | N/M | N/M | -131.2% | -169.4% | -199.2% | -196.6% | -73.7% | N/M |
| ROE | N/A | N/A | N/A | 158.6% | 92.8% | 44.7% | 259.7% | -73.6% | 83.3% | 66.4% | 106.3% | 79.4% | 0.0% |
| ROA | -360.5% | -180.3% | -138.8% | -146.2% | -145.6% | -117.9% | -2433.6% | 490.4% | -293.9% | -217.5% | -312.1% | -113.8% | -75.6% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -55M | -79M | -56M | -36M | -35M | -32M | -32M | 38M | -53M | -54M | -57M | -45M | -45M |
| Free Cash Flow | -88M | -85M | -61M | -37M | -35M | -32M | -32M | 38M | -53M | -54M | -58M | -46M | -46M |
| Owner Earnings | -55M | -82M | -56M | -38M | -50M | -34M | -84M | 22M | -66M | -59M | -62M | -48M | -48M |
| CapEx | 34M | 6.8M | 4.9M | 8K | 0 | 171K | 0 | 0 | 0 | 0 | 1.0M | 1.5M | 1.5M |
| Maint. CapEx | 11K | 56K | 405K | 559K | 1.3M | 21K | 87K | 324K | 1.3M | 1.5M | 1.7M | 2.1M | 2.1M |
| Growth CapEx | 34M | 6.7M | 4.5M | 0 | N/A | 150K | N/A | N/A | N/A | N/A | 0 | 0 | 0 |
| D&A | 11K | 56K | 405K | 559K | 1.3M | 21K | 87K | 324K | 1.3M | 1.5M | 1.7M | 2.1M | 2.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 0 | 3.4M | 127K | 842K | 14M | 1.8M | 52M | 16M | 12M | 3.6M | 3.5M | 1.2M | 1.2M |
| Debt Repayment | 622K | 138K | 0 | 3.3M | 1.0M | 1.2M | 89K | 5.8M | 0 | 0 | 1.1M | 1.0M | 1.0M |
| Balance Sheet | |||||||||||||
| Net Debt | -28M | -21M | 26M | 42M | 1.8M | 23M | 12M | 30M | 35M | 47M | 79M | 71M | 71M |
| Cash & Equiv. | 13M | 22M | 6.9M | 117K | 22M | 372K | 10.0M | 15M | 7.0M | 2.1M | 2.2M | 3.0M | 3.0M |
| Long-Term Debt | 500K | 23M | 32M | 31M | 17M | 13M | 15M | 32M | 22M | 41M | 63M | 60M | 60M |
| Debt/Equity | -0.04 | -5.08 | -1.49 | -0.62 | -0.50 | -0.52 | -0.06 | -0.36 | -0.33 | -0.75 | -0.86 | -1.23 | 0.00 |
| Interest Coverage | -101.5 | -30.4 | -20.8 | -9.9 | -4.2 | -9.4 | -10.1 | -10.5 | -11.1 | -10.6 | -8.6 | -6.9 | -6.9 |
| Equity | -35M | -4.7M | -26M | -67M | -48M | -45M | -363M | -124M | -128M | -66M | -94M | -60M | -60M |
| Total Assets | 56M | 71M | 53M | 49M | 25M | 11M | 33M | 40M | 31M | 28M | 27M | 81M | 81M |
| Total Liabilities | 91M | 75M | 79M | 116M | 73M | 56M | 396M | 164M | 159M | 94M | 121M | 142M | 142M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | 0 | 1.3M | 1.3M | 1.3M | 1.3M | 1.3M | 53M | 53M |
| Retained Earnings | N/A | N/A | 5.6M | -789M | -824M | -841M | -1.4B | -1.2B | -1.3B | -1.4B | -1.4B | -1.5B | -1.5B |
| Working Capital | -60M | -41M | -69M | -86M | -46M | -41M | -367M | -116M | -117M | -41M | -64M | -86M | -86M |
| Current Assets | 15M | 24M | 7.9M | 1.4M | 24M | 3.2M | 16M | 17M | 9.4M | 4.1M | 4.1M | 5.5M | 5.5M |
| Current Liabilities | 75M | 65M | 76M | 88M | 70M | 44M | 382M | 134M | 126M | 45M | 68M | 92M | 92M |
| Per Share Data | |||||||||||||
| EPS | -2.29 | -1.48 | -0.77 | -0.31 | -0.12 | -0.04 | -0.73 | 0.19 | -0.10 | -0.06 | -0.07 | -0.04 | -0.04 |
| Owner EPS | -0.92 | -1.06 | -0.50 | -0.16 | -0.11 | -0.06 | -0.12 | 0.02 | -0.06 | -0.05 | -0.05 | -0.03 | -0.03 |
| Book Value | -0.59 | -0.06 | -0.24 | -0.28 | -0.11 | -0.09 | -0.50 | -0.13 | -0.12 | -0.06 | -0.08 | -0.04 | -0.04 |
| Cash Flow/Share | -0.92 | -1.01 | -0.50 | -0.15 | -0.08 | -0.06 | -0.04 | 0.04 | -0.05 | -0.05 | -0.05 | -0.03 | -0.04 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 59.2M | 77.5M | 111.5M | 240.0M | 446.3M | 520.3M | 725.8M | 948.4M | 1.1B | 1.1B | 1.2B | 1.5B | 1.5B |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 17.3 | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -27.1% | -32.9% | -41.7% | -63.4% | -36.9% | -28.0% | -2.5% | 5.1% | -6.1% | -6.8% | -17.7% | N/A | -17.5% |
| Market Cap | 326M | 260M | 145M | 58M | 94M | 114M | 1.3B | 751M | 861M | 783M | 329M | 0 | 264M |
| Avg. Price | 5.87 | 7.44 | 1.02 | 0.24 | 0.25 | 0.26 | 0.55 | 1.33 | 0.79 | 0.66 | 0.42 | 0.00 | 0.17 |
| Year-End Price | 5.50 | 3.35 | 0.35 | 0.24 | 0.21 | 0.22 | 1.76 | 0.70 | 0.82 | 0.73 | 0.27 | 0.00 | 0.17 |
NORTHWEST BIOTHERAPEUTICS INC passes 1 of 9 quality checks, indicating weak fundamentals.
The Ledger Terminal provides 16 years of financial data for NORTHWEST BIOTHERAPEUTICS INC (NWBO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) has a book value per share of $-0.04, based on its most recent annual SEC filing.